ReviewMevalonate pathway: A review of clinical and therapeutical implications
Introduction
Mevalonate pathway is an important metabolic pathway that provides cells with essential bioactive molecules, vital in multiple cellular processes. This pathway converts mevalonate into sterol isoprenoids, such as cholesterol, indispensable precursor of bile acids, lipoproteins, and steroid hormones, and into a number of hydrophobic molecules, nonsterol isoprenoids. These intermediates of the mevalonate biosynthetic pathway play important roles in the post-translational modification of a multitude of proteins involved in intracellular signaling and are essential in cell growth/differentiation, gene expression, protein glycosylation and cytoskeletal assembly [1], [2].
Section snippets
Biochemistry of the mevalonate pathway
The mevalonate–isoprenoid pathway involves first the synthesis of 3-hydroxy-3-methylglutaryl-CoA (HMG)-CoA from acetyl-CoA through acetoacetylCoA. 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR), one of the most highly regulated enzymes in nature, catalyzes the conversion of HMG-CoA to mevalonic acid. HMGR is the rate-limiting enzyme of mevalonate pathway [1]. In the absence of sterol isoprenoids in the cell, HMGR gene transcription is directly activated by a family transcription factors, named
Clinical implications
The clinical importance of isoprenoid biosynthesis for human health has been extensively demonstrated. The decreased activity of one of the key enzymes of the mevalonate pathway, mevalonate kinase (MK), has been identified as the direct biochemical and molecular cause of two inherited human autoinflammatory disorders: mevalonic aciduria (MVA) and hyperimmunoglobulinemia D syndrome (HIDS). MVA is characterized by psychomotor retardation, failure to thrive, progressive cerebellar ataxia,
Mevalonate pathway as a therapeutic target
Rational therapeutical manipulation of the mevalonate pathway and downstream isoprenoid biosynthesis pathway by statins and bisphosphonates has been intensively studied and found to be an interesting and revolutionary option in a variety of diseases, by mechanisms unrelated to changes of cholesterol and bone metabolism, respectively. Although this mechanism has yet to be fully elucidated and many controversies still exist, essentially because of the observed differences between the experimental
References (133)
- et al.
Post-translational regulation of mevalonate kinase by intermediates of the cholesterol and nonsterol isoprene biosynthetic pathways
J. Lipid Res.
(1997) - et al.
Sterol regulatory element-binding proteins induce an entire pathway of cholesterol synthesis
Biochem. Biophys. Res. Commun.
(2001) - et al.
Regulation of isoprenoid/cholesterol biosynthesis in cells from mevalonate kinase-deficient patients
J. Biol. Chem.
(2003) Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase
Am. Heart J.
(2002)Statin inhibition of HMG-CoA reductase: a 3-dimensional view
Atheroscler. Suppl.
(2003)- et al.
The structure of the catalytic portion of human HMG-CoA reductase
Biochim. Biophys. Acta
(2000) - et al.
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
Am. J. Cardiol.
(1998) - et al.
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)
Am. J. Cardiol.
(2003) - et al.
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Lancet
(2003) - et al.
CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomised placebo-controlled trial
Lancet
(2004)